Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Novembre E.; Tosca M.; Caffarelli C.; Calvani M.; Cardinale F.; Castagnoli R.; Chiappini E.; Cravidi C.; Del Giudice M. M.; Duse M.; Licari A.; Manti S.; Martelli A.; Ricci G.; Pingitore G.; Marseglia G. L.

doi:10.1186/s13052-022-01272-z

BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP) / Novembre E.; Tosca M.; Caffarelli C.; Calvani M.; Cardinale F.; Castagnoli R.; Chiappini E.; Cravidi C.; Del Giudice M.M.; Duse M.; Licari A.; Manti S.; Martelli A.; Ricci G.; Pingitore G.; Marseglia G.L.. - In: THE ITALIAN JOURNAL OF PEDIATRICS. - ISSN 1720-8424. - ELETTRONICO. - 48:(2022), pp. 76-0. [10.1186/s13052-022-01272-z]